Racialization Of Drugs Mobilizes Prior Conceptions Of Identity If we want to fully understand the allure of pharmaceuticals, we need to look beyond both medical efficacy and profit motives. A new study in the Journal of Law,
Medicine & Ethics shows that when we use claims about
drugs in arguments about racial identity, the meaning of both the pharmaceuticals and of race remain unsettled. Anne Pollock, Ph.D. of the Georgia Institute of Technology tracks the intersection of race and a particular generic drug, thiazide.
Source: www.medicalnewstoday.comBG-12, Biogen Idec's Novel Oral Compound Shown To Significantly Reduced Brain Lesions In Patients With Multiple Sclerosis Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
